Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2511 in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs E 2511 (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Eisai Inc

Most Recent Events

04 Aug 2022 Results from NCT04547361 and NCT05147337 evaluating the safety, tolerability and pharmacokinetics in healthy subjects, presented at the Alzheimer's Association International Conference 2022
07 Jul 2021 Status changed from recruiting to completed.
23 Apr 2021 Planned End Date changed from 14 Apr 2021 to 25 May 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com